期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性非淋巴性白血病的化疗药物利用及成本分析 被引量：1

在线阅读 下载PDF
导出
摘要 目的　了解急性非淋巴性白血病 (ANLL)患者化疗药物利用及成本消耗情况。方法　回顾性调查分析我院 1 999年 1月至 2 0 0 0年 1 2月 60名ANLL患者的 1 59次化疗情况。结果　药品支出比例偏高 ,占住院费的 61 .45 %。化疗药中出现频次最多的是阿糖胞苷 ,最常用的化疗方案是柔红霉素 +阿糖胞苷 (DA方案 )。平均每次化疗药品金额为 (3 80 3 .2 6± 4 589.2 5)元 (1 2 7.40～ 1 9780 .0 0元 ) ;化疗药品费为住院费的 1 6 .1 9%。
作者 郭代红 张志萍 朱秀美 王波 任浩洋 刘敏超 郝珍
机构地区 解放军总医院
出处 《中国药学杂志》 CAS CSCD 北大核心 2003年第2期143-144,共2页 Chinese Pharmaceutical Journal
关键词 急性非淋巴性白血病 化疗药物 成本分析 药物成本 药物经济学
分类号 R733.7 [医药卫生—肿瘤] F407.7 [经济管理—产业经济]
  • 相关文献

参考文献5

二级参考文献5

共引文献46

同被引文献13

  • 1Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeIoid leukemia in Sweden[J ]. Int J Tecbaxol Assess Health Care, 1994, 10:683 - 94.
  • 2Uyl - de Groot CA, Gelderblom- den I-lartog J, Huijgens PC, et al. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands[J ]. J Hematother Stem Cell Res, 2001, 10:187 - 92.
  • 3Menzin J, Lang K, Earle CC, et al. The outcomes and costs of a- cute myeloid leukemia among the elderly[J]. Arch Intern Med, 2002, 162(14):1 597-1 603.
  • 4Yu YB, Gau JP, You JY, et al. Cost- effectiveness of postrem- ission intensive therapy in paticmts with acute leukemia[J ]. Ann Oncol, 2007, 18:529 - 34.
  • 5Huang BT, Wang Y, Du OF, et al. Analysis of efficacy and cost - effectiveness of high - dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China[J ]. Int J Hernatol, 2011, 93:474 - 81.
  • 6Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mi- toxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the E- OR'F(] and GIMEMA Groups Study AML - 10[J]. J Clin Oncol, 2009, 27:5 397 - 5 403.
  • 7van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA- identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaaaia or acute lympboblastic leukaemia [J]. Bone Marrow Transplant, 2002;30:243 - 51.
  • 8Bennett CL, Hynes D, Godwin J, et al. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelngenous leukemia (AML): estimates from a southwest oncology group clinical trial[J ]. Cancer Invest, 2001, 19:603 - 10.
  • 9Beksac M, Ali R, Ozcelik T, et al. Short and long term effects of granulocyte colony- stimulathn4g factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a ran- domized multicenter phase III trial [ J ]. Leuk Res, 2011, 35 : 340 -5.
  • 10Bennett CL, Bishop MR, Tallman MS, et al. The association be- tween physician reimbursenent in the US and use of hematopoiet- ic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American So- ciety of Clinical Oncolc'3r survey. Health Services Research Com- mittee of the American Society of Clinical Oncology[J]. Ann On- col. 1999.10:1355 - 9.

引证文献1

中国药学杂志
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部